vs
CoStar Group（CSGP）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是CoStar Group的1.7倍（$1.5B vs $899.9M），Steris净利率更高（12.9% vs 5.2%，领先7.7%），CoStar Group同比增速更快（26.9% vs 9.2%），Steris自由现金流更多（$199.5M vs $101.3M），过去两年CoStar Group的营收复合增速更高（17.1% vs 15.8%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
CSGP vs STE — 直观对比
营收规模更大
STE
是对方的1.7倍
$899.9M
营收增速更快
CSGP
高出17.7%
9.2%
净利率更高
STE
高出7.7%
5.2%
自由现金流更多
STE
多$98.2M
$101.3M
两年增速更快
CSGP
近两年复合增速
15.8%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $1.5B |
| 净利润 | $46.5M | $192.9M |
| 毛利率 | 78.6% | 43.8% |
| 营业利润率 | 5.5% | 18.3% |
| 净利率 | 5.2% | 12.9% |
| 营收同比 | 26.9% | 9.2% |
| 净利润同比 | -22.2% | 11.2% |
| 每股收益（稀释后） | $0.12 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPSTE
| Q4 25 | $899.9M | $1.5B | ||
| Q3 25 | $833.6M | $1.5B | ||
| Q2 25 | $781.3M | $1.4B | ||
| Q1 25 | $732.2M | $1.5B | ||
| Q4 24 | $709.4M | $1.4B | ||
| Q3 24 | $692.6M | $1.3B | ||
| Q2 24 | $677.8M | $1.3B | ||
| Q1 24 | $656.4M | $1.1B |
净利润CSGPSTE
| Q4 25 | $46.5M | $192.9M | ||
| Q3 25 | $-30.9M | $191.9M | ||
| Q2 25 | $6.2M | $177.4M | ||
| Q1 25 | $-14.8M | $145.7M | ||
| Q4 24 | $59.8M | $173.5M | ||
| Q3 24 | $53.0M | $150.0M | ||
| Q2 24 | $19.2M | $145.4M | ||
| Q1 24 | $6.7M | $-1.4M |
毛利率CSGPSTE
| Q4 25 | 78.6% | 43.8% | ||
| Q3 25 | 79.3% | 44.2% | ||
| Q2 25 | 78.5% | 45.1% | ||
| Q1 25 | 79.1% | 43.3% | ||
| Q4 24 | 80.1% | 44.5% | ||
| Q3 24 | 79.7% | 43.6% | ||
| Q2 24 | 80.0% | 44.7% | ||
| Q1 24 | 78.5% | 40.2% |
营业利润率CSGPSTE
| Q4 25 | 5.5% | 18.3% | ||
| Q3 25 | -6.1% | 18.2% | ||
| Q2 25 | -3.5% | 17.7% | ||
| Q1 25 | -5.8% | 14.6% | ||
| Q4 24 | 5.6% | 17.9% | ||
| Q3 24 | 3.4% | 16.5% | ||
| Q2 24 | -2.4% | 14.5% | ||
| Q1 24 | -6.5% | 22.0% |
净利率CSGPSTE
| Q4 25 | 5.2% | 12.9% | ||
| Q3 25 | -3.7% | 13.1% | ||
| Q2 25 | 0.8% | 12.8% | ||
| Q1 25 | -2.0% | 9.8% | ||
| Q4 24 | 8.4% | 12.7% | ||
| Q3 24 | 7.7% | 11.3% | ||
| Q2 24 | 2.8% | 11.4% | ||
| Q1 24 | 1.0% | -0.1% |
每股收益（稀释后）CSGPSTE
| Q4 25 | $0.12 | $1.96 | ||
| Q3 25 | $-0.07 | $1.94 | ||
| Q2 25 | $0.01 | $1.79 | ||
| Q1 25 | $-0.04 | $1.48 | ||
| Q4 24 | $0.14 | $1.75 | ||
| Q3 24 | $0.13 | $1.51 | ||
| Q2 24 | $0.05 | $1.46 | ||
| Q1 24 | $0.02 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $423.7M |
| 总债务越低越好 | $140.0M | $1.9B |
| 股东权益账面价值 | $8.3B | $7.2B |
| 总资产 | $10.5B | $10.6B |
| 负债/权益比越低杠杆越低 | 0.02× | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资CSGPSTE
| Q4 25 | $1.6B | $423.7M | ||
| Q3 25 | $1.9B | $319.2M | ||
| Q2 25 | $3.6B | $279.7M | ||
| Q1 25 | $3.7B | $171.7M | ||
| Q4 24 | $4.7B | $155.2M | ||
| Q3 24 | — | $172.2M | ||
| Q2 24 | — | $198.3M | ||
| Q1 24 | — | $207.0M |
总债务CSGPSTE
| Q4 25 | $140.0M | $1.9B | ||
| Q3 25 | $1.0B | $1.9B | ||
| Q2 25 | $1.0B | $1.9B | ||
| Q1 25 | $1.0B | $1.9B | ||
| Q4 24 | $1.0B | $2.0B | ||
| Q3 24 | $1.0B | $2.2B | ||
| Q2 24 | $1.0B | $2.2B | ||
| Q1 24 | $1.0B | $3.1B |
股东权益CSGPSTE
| Q4 25 | $8.3B | $7.2B | ||
| Q3 25 | $8.6B | $7.0B | ||
| Q2 25 | $8.6B | $7.0B | ||
| Q1 25 | $8.6B | $6.6B | ||
| Q4 24 | $7.6B | $6.4B | ||
| Q3 24 | $7.5B | $6.6B | ||
| Q2 24 | $7.4B | $6.4B | ||
| Q1 24 | $7.3B | $6.3B |
总资产CSGPSTE
| Q4 25 | $10.5B | $10.6B | ||
| Q3 25 | $10.8B | $10.4B | ||
| Q2 25 | $10.5B | $10.4B | ||
| Q1 25 | $10.4B | $10.1B | ||
| Q4 24 | $9.3B | $10.0B | ||
| Q3 24 | $9.1B | $10.2B | ||
| Q2 24 | $9.1B | $10.1B | ||
| Q1 24 | $9.0B | $11.1B |
负债/权益比CSGPSTE
| Q4 25 | 0.02× | 0.27× | ||
| Q3 25 | 0.12× | 0.27× | ||
| Q2 25 | 0.12× | 0.27× | ||
| Q1 25 | 0.12× | 0.29× | ||
| Q4 24 | 0.13× | 0.32× | ||
| Q3 24 | 0.13× | 0.33× | ||
| Q2 24 | 0.14× | 0.35× | ||
| Q1 24 | 0.14× | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $199.5M |
| 自由现金流率自由现金流/营收 | 11.3% | 13.3% |
| 资本支出强度资本支出/营收 | 6.8% | 6.6% |
| 现金转化率经营现金流/净利润 | 3.49× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $123.0M | $917.1M |
8季度趋势，按日历期对齐
经营现金流CSGPSTE
| Q4 25 | $162.1M | $298.2M | ||
| Q3 25 | $68.2M | $287.8M | ||
| Q2 25 | $146.5M | $420.0M | ||
| Q1 25 | $53.2M | $260.8M | ||
| Q4 24 | $94.6M | $332.8M | ||
| Q3 24 | $100.3M | $250.7M | ||
| Q2 24 | $58.1M | $303.7M | ||
| Q1 24 | $139.6M | $254.8M |
自由现金流CSGPSTE
| Q4 25 | $101.3M | $199.5M | ||
| Q3 25 | $-5.5M | $201.3M | ||
| Q2 25 | $27.7M | $326.4M | ||
| Q1 25 | $-500.0K | $189.9M | ||
| Q4 24 | $25.2M | $243.6M | ||
| Q3 24 | $40.2M | $148.8M | ||
| Q2 24 | $-14.7M | $195.7M | ||
| Q1 24 | $-237.1M | $163.3M |
自由现金流率CSGPSTE
| Q4 25 | 11.3% | 13.3% | ||
| Q3 25 | -0.7% | 13.8% | ||
| Q2 25 | 3.5% | 23.5% | ||
| Q1 25 | -0.1% | 12.8% | ||
| Q4 24 | 3.6% | 17.8% | ||
| Q3 24 | 5.8% | 11.2% | ||
| Q2 24 | -2.2% | 15.3% | ||
| Q1 24 | -36.1% | 14.6% |
资本支出强度CSGPSTE
| Q4 25 | 6.8% | 6.6% | ||
| Q3 25 | 8.8% | 5.9% | ||
| Q2 25 | 15.2% | 6.7% | ||
| Q1 25 | 7.3% | 4.8% | ||
| Q4 24 | 9.8% | 6.5% | ||
| Q3 24 | 8.7% | 7.7% | ||
| Q2 24 | 10.7% | 8.4% | ||
| Q1 24 | 57.4% | 8.2% |
现金转化率CSGPSTE
| Q4 25 | 3.49× | 1.55× | ||
| Q3 25 | — | 1.50× | ||
| Q2 25 | 23.63× | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | 1.58× | 1.92× | ||
| Q3 24 | 1.89× | 1.67× | ||
| Q2 24 | 3.03× | 2.09× | ||
| Q1 24 | 20.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
